
|Articles|July 1, 2004
Fighting melanoma
New Orleans - Oblimersen sodium (Genasense), the antisense agent under investigation for advanced malignant melanoma, improved progression-free survival but not overall survival, in a recent phase III trial, Michael J. Millward, M.D. reported here at the annual meeting of the American Society of Clinical Oncology (ASCO).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
2
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
5











